|
BMI <30 kg/m2
|
BMI ≥30 kg/m2
|
Continuous Use
Celecoxib
200 mg qd
n=209
n (%) |
Intermittent Use
Celecoxib
200 mg qd
n=205 n (%) |
Continuous Use
Celecoxib
200 mg qd
n=222
n (%) |
Intermittent Use
Celecoxib
200 mg qd
n=222
n (%) |
Total no. patients with AE |
114 (54.5) |
121 (59.0) |
131 (59.0) |
130 (58.6) |
AE ≥2% Patients in Either Treatment Group by Preferred Term |
Headache |
33 (15.8) |
32 (15.6) |
32 (14.4) |
36 (16.2) |
Back pain |
10 (4.8) |
20 (9.8) |
10 (4.5) |
11 (5.0) |
Arthralgia |
9 (4.3) |
14 (6.8) |
8 (3.6) |
11 (5.0) |
Nasopharyngitis |
7 (3.3) |
8 (3.9) |
12 (5.4) |
12 (5.4) |
Diarrhea |
1 (0.5) |
11 (5.4) |
6 (2.7) |
6 (2.7) |
Pain in extremity |
9 (4.3) |
10 (4.9) |
9 (4.1) |
11 (5.0) |
Dyspepsia |
6 (2.9) |
3 (1.5) |
11 (5.0) |
3 (1.4) |
Upper respiratory tract infection |
7 (3.3) |
9 (4.4) |
7 (3.2) |
10 (4.5) |
Hypertension |
2 (1.0) |
9 (4.4) |
7 (3.2) |
4 (1.8) |
Upper abdominal pain |
3 (1.4) |
9 (4.4) |
4 (1.8) |
1 (0.5) |
Sinusitis |
5 (2.4) |
1 (0.5) |
6 (2.7) |
9 (4.1) |
Musculoskeletal pain |
4 (1.9) |
3 (1.5) |
3 (1.4) |
9 (4.1) |
Insomnia |
3 (1.4) |
6 (2.9) |
8 (3.6) |
2 (0.9) |
Edema peripheral |
3 (1.4) |
5 (2.4) |
1 (0.5) |
7 (3.2) |
Bronchitis |
2 (1.0) |
2 (1.0) |
1 (0.5) |
7 (3.2) |
Muscle spasms |
7 (3.3) |
1 (0.5) |
3 (1.4) |
4 (1.8) |
Dizziness |
6 (2.9) |
6 (2.9) |
2 (0.9) |
2 (0.9) |
Nausea |
2 (1.0) |
6 (2.9) |
3 (1.4) |
3 (1.4) |
Abdominal pain |
4 (1.9) |
2 (1.0) |
6 (2.7) |
2 (0.9) |
Contusion |
1 (0.5) |
1 (0.5) |
2 (0.9) |
6 (2.7) |
Myalgia |
4 (1.9) |
4 (2.0) |
6 (2.7) |
5 (2.3) |
Toothache |
1 (0.5) |
4 (2.0) |
2 (0.9) |
2 (0.9) |
Fatigue |
0 (0) |
6 (2.9) |
6 (2.7) |
3 (1.4) |
Pain |
4 (1.9) |
6 (2.9) |
2 (0.9) |
3 (1.4) |
Influenza |
5 (2.4) |
4 (2.0) |
5 (2.3) |
5 (2.3) |
Vomiting |
1 (0.5) |
4 (2.0) |
4 (1.8) |
2 (0.9) |
Viral infection |
0 (0) |
4 (2.0) |
3 (1.4) |
0 (0) |
Rash |
0 (0) |
4 (2.0) |
1 (0.5) |
3 (1.4) |